Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with SCLC

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.10.18
Views: 1049
Rating:

Prof Jean-Louis Pujol - CHRU de Montpellier, Hôpital Arnaud de Villeneuve, Montpellier, France

Prof Jean-Louis Pujol peaks with ecancer at ESMO 2018 in Munich about the study into the use of anti–PD-L1 atezolizumab or chemotherapy as second-line therapy in patients with small cell lung cancer.

Prof Pujol explains that they found that only 1 patient out of 49 in the atezolizumab group had a response at 6 weeks.

He states that the progression-free survival differed significantly in the two groups in favour of the chemotherapy, and the difference in overall survival was not tangible.

For more in SCLC, Dr Noemi Reguart gave her conference highlights here.

ecancer's filming has been kindly supported by MSD through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Related videos

follow us

Donate to ecancer


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation